Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674100 · ClinicalTrials.gov registry record
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
A clinical trial of Pancreatic Cancer, sponsored by University of Louisville.
- Recruiting
- Registry status
- 500
- Enrollment target
- 16
- Study locations
NCT02674100: Recruiting study of Pancreatic Cancer, sponsored by University of Louisville.
NCT02674100 is a study of Pancreatic Cancer that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 500 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02674100, a study of Pancreatic Cancer, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
Primary Outcome
Prospective collection of All Adverse Events that will be categorized as either IRE related or Non-IRE related and will be graded per CTCAE v4.0
Conditions Studied
Interventions
- OTHER Registry
Study Locations (16)
Other
- Centro Medico - Mexico City
- National Taiwan University - Taipei
- Freeman Hospital - High Heaton
Alabama
- University of Alabama Birmingham - Birmingham
California
- University of California San Diego - San Diego
Colorado
- University of Colorado - Denver
Florida
- University of South Florida - Tampa
Georgia
- Augusta University - Augusta
Kentucky
- University of Louisville - Louisville
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2016-01 |
| Est. Completion | 2030-01 |
What NCT02674100 shows while recruiting
NCT02674100 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Registry is the first listed.
NCT02674100 lists 16 locations in 14 states (Other, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT02674100 about?
NCT02674100 is a clinical study titled "American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry". The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The...
What is the current status of trial NCT02674100?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2016-01. Estimated completion is 2030-01.
What conditions does trial NCT02674100 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT02674100?
The interventions under investigation include: Registry (OTHER).
Who is sponsoring clinical trial NCT02674100?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02674100 being conducted?
This trial has 16 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02674100's enrollment target sits among peer trials
500 30th of 278 higher than 247 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia